- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04279535
Topical Vitamin C for Treatment of Basal Cell Cancer
Topical Ascorbic Acid for Treatment of Basal Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Importance
Skin cancer is the most common cancer in the United States, with more people diagnosed each year than all other cancers combined (1). Basal cell cancer is the most common form with an estimated 4.3 million cases diagnosed annually (2,3). Costs of treating this cancer in the U.S. are estimated at $4.8 billion annually (4). Task force consensus guidelines suggest Mohs surgery as the treatment of choice, and as the single most precise and effective treatment method (5). However, cost and issues of cosmesis are principal disadvantages.
Objective
To evaluate efficacy of a therapeutic regimen in treating basal cell cancer, consisting of 30% ascorbic acid in 95% dimethylsulfoxide topically applied at home by patients twice a day for 8 weeks, vs 5% imiquimod cream which is an FDA approved treatment for BCC.
Design, Setting, and Participants This study was carried out in accordance with principles of the Declaration of Helsinki. Detailed informed consent was obtained from each patient.
Eligible participants of any age had histologically confirmed primary, previously untreated, nodular or superficial BCC not arising at sites of high risk for sub clinical tumor spread (the nose, ear, eyelid, eyebrow, or temple ( )). Patients with infiltrative, recurrent, or morphoeic BCC were excluded from the study. Imiquimod was applied once daily for 5 days per week as per manufacturer instructions for treatment of BCC. Patients were randomly assigned to treatment group. Participants and outcome assessors were blinded to treatment protocol. Patients were seen at initial visit, 4 weeks, 8 weeks, and six weeks after treatment conclusion for final biopsy. Those participants in the IMQ group who continued through 12 weeks of treatment were seen for an additional visit. The AA treatment was a solution while the IMQ a cream, however participants were simply told they would be receiving a topical treatment with instructions on how to apply, thus the blinding remained intact.
Histopathology showed 21 nodular and 8 superficial BCC subtypes upon enrollment. Thirteen patients (8 female 5 male) with a total of 15 lesions were randomized to the ascorbic acid (AA) treatment group, and 12 patients (6 female 6 male) with 14 lesions were randomized to the imiquimod group (IMQ). There was no difference in mean size of BCC in each group ( 11.4 +/-2.1 mm vs. 13.1 +/- 1.9mm). The AA group had 11 nodular and 4 superficial BCC and the IMQ group 10 nodular and 4 superficial.
Histopathology was confirmed by 2mm partial punch biopsy leaving
the bulk of the BCC intact prior to treatment. Patients in the AA group were treated
twice daily 7 days per week with a topical solution of 30% (w/v) ascorbic acid solution in 95% (v/v) dimethylsulfoxide (DMSO) and
5% (v/v) distilled water, while the IMQ patients received twice daily application of a commercial 5% cream 5 days per week according to manufacturer recommendations for treatment of BCC. Application was made with a small cuticle brush in the AA group. Patient compliance was high and no
patient had difficulty with the application. Volume of the ascorbic acid solution applied was 0.2-0.3ml per application. Treatment was
continued for 8 wks or until the lesion cleared. Subjects in the IMQ group whose lesions had failed to resolve at 8 weeks were treated for an additional 4 weeks in conformity with reports showing better outcomes with 12 weeks of treatment with IMQ ( ).
All patients had an appointment set for Mohs surgery
after study enrollment, so in the event of treatment failure no further delay in definitive treatment would occur.
Repeat 2mm punch biopsy of each site was taken at the conclusion of the study. Patients were seen in follow up after
12, 24, and 30 months
Interventions
An 8 wk therapeutic regimen of topical 30% (w/v) ascorbic acid, 95% (v/v) dimethylsulfoxide, and 5% (v/v) distilled water applied twice daily at home, or 5% imiquimod cream applied 5/wk according to manufacturer recommendations for treating BCC.
Main Outcomes and Measures
Number of lesions out that were cancer free after 8 wks of treatment.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Center for Biomedical Research,Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of biopsy proven basal cell carcinoma
Exclusion Criteria:
- Absence of basal cell carcinoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ascorbic acid
Participants applied topical solution of ascorbic acid twice daily for 8 weeks
|
Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
|
Active Comparator: Imiquimod
Participants applied 5% imiquimod cream topically 5x/week
|
Twice daily application of 300 microliters of 30% ascorbic acid solution with a small cuticle brush.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lesion Resolution
Time Frame: 8 weeks
|
Number of lesions resolved out of total of 6 treated.
|
8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Briant Burke, MD, CBR,Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCC-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Graceway Pharmaceuticals, LLCCompletedSuperficial Basal Cell CarcinomaAustralia, New Zealand
-
Biofrontera Bioscience GmbHAccovion GmbHCompletedBasal Cell Carcinoma (BCC)Germany
-
Berg, LLCCompletedSuperficial Basal Cell CarcinomaUnited States
-
PeplinCompletedSuperficial Basal Cell CarcinomaAustralia
Clinical Trials on Topical Ascorbic Acid
-
Sohag UniversityCompletedAcne Scars | Acne VulgarisEgypt
-
Harokopio UniversityCompletedSymptomatic Knee OsteoarthritisGreece
-
Situs Cancer Research CenterSuspendedSarcoma | Adenocarcinoma | Carcinoma | Multiple Myeloma | Desmoplastic Small Round Cell TumorUnited States
-
DongGuk UniversityKorean Association For Vitamin ResearchCompleted
-
National Taiwan University Hospital Hsin-Chu BranchCompletedHemodialysis Access Failure
-
Sisli Hamidiye Etfal Training and Research HospitalCompletedCovid19 | Respiratory Distress Syndrome, AdultTurkey
-
Swiss Federal Institute of TechnologyCompletedIron-deficiency | Iron Deficiency AnemiaSwitzerland
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Unknown
-
Jewish General HospitalCompleted